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Abstract
Oculogyric crisis is a rare ocular dystonia first appearing at the turn of the last century in
postencephalitic patients. In the modern era, they were most frequently associated with first-
generation D1 dopaminergic receptor blocking antipsychotic medication.
We present an unusual case of acute oculogyric crisis in a 74-year-old woman with long-
standing Parkinson disease following exposure to the second-generation neuroleptic
ziprasidone, which has dopaminergic (D2) and serotoninergic (5-HT2A) receptor blocking
effects and is used for severe delusions and psychosis. To the best of our knowledge, there are
no other published reports.
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Introduction
Acute motor adverse events are common with the use of first-generation typical anti-
dopaminergic medications prompting the development of atypical second-generation agents
[1]. These motor disorders are divided into akathisias (10%-40%), acute dystonias (2%-3%) and
neuroleptic malignant syndrome (0.2%). Acute dystonias are motor disorders characterized by
uncontrollable muscular contractions usually occurring within days of exposure to the inciting
medication typically restricted to the musculature of the head, pharynx, cervical spine and
trunk [1]. 
Oculogyric crisis (OGC) is the rarest of the acute dystonias presenting as involuntary painless
contractions of the extraocular muscles resulting in sustained upward eye deviation [2]. These
episodes may last for minutes to hours. Their mechanism of action is unknown but possibly due
to acute selective dopaminergic blockade [3].
We report a case of acute OGC in a hospitalized 74-year-old woman approximately one month
following outpatient administration of ziprasidone. Ziprasidone is a commonly prescribed
second-generation atypical neuroleptic with antiserotonin and antidopaminergic effects. There
are four previously reported cases of ziprasidone-associated OGC in patients treated for
schizophrenia [4-7]. This is the first case of ziprasidone-induced OGC in a patient with
advanced Parkinson disease.
Case Presentation
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Our patient is a 74-year-old woman with a past medical history of long-standing Parkinson
disease, diabetes mellitus and hypothyroidism who presented to the emergency department
with generalized weakness and episodic confusion. She complained of troubling sialorrhea,
dysphagia, random eye movement behavioral sleep disorder and visual hallucinations. For
three days, she complained of frequent spasm of her eyelids during this time among other
somatic concerns. She denied pain with eye movement but had no self-awareness as to whether
she was in control of her eyes and eyelid spasms. She was prescribed pimavanserin for psychosis
and rivastigmine for memory loss.
Her current medications at the time included carbidopa/levodopa, liothyronine, rivastigmine,
clonazepam, levothyroxine and pimavanserin. Our initial diagnosis was toxic encephalopathy
in the setting of her Parkinson disease and dementia. On physical examination, she was alert
and able to follow commands when not in crisis. On neurologic examination, she exhibited
hypomimia with marked four limb rigidity and bradykinesia. During the crisis there was
intermittent sustained upward deviation noted of the eyes compounded by a decrease in
mentation (Video 1). When the crisis was over, her eye movements were intact. There was no
associated neck deviation or tongue protrusion. 
VIDEO 1: Intermittent sustained upward deviation of the eyes
seen on physical exam.
View video here: https://vimeo.com/404684202
Lab work including complete blood count, urinalysis, blood culture and a chest x-ray did not
reveal infection. A CT image of the head demonstrated an extra-axial hematoma from the left
frontal bone (Figure 1).
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FIGURE 1: A CT image of the head demonstrates an extra-axial
hematoma overlying the frontal bone. This finding is not
relevant to the case report, as a hematoma cannot cause an
oculogyric crisis.
This was thought to be a potential seizure focus and the etiology of her encephalopathy. Her
marked rigidity and altered mental status raised concerns of neuroleptic malignant syndrome
but lack of fever opposed this hypothesis. MRI of the brain showed small vessel disease and a
right parietal and pontine cavernoma (Figure 2).
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FIGURE 2: MRI of the brain demonstrates small vessel disease
(black arrow) and a right parietal and pontine cavernoma
(white arrow).
Electroencephalogram was negative for epileptiform activity (Figure 3). Her husband revealed
she was recently treated for severe delusions and psychosis with the atypical antidopaminergic
agent ziprasidone within the last month. 
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FIGURE 3: Electroencephalogram without epileptiform activity.
She was diagnosed with OGC secondary to exposure to a second-generation antipsychotic.
First- and second-line treatments, namely benztropine, diphenhydramine and
benzodiazepines, were not prescribed for fear of depressing an already compromised mental
state. Her carbidopa/levodopa dosage was subsequently increased to 1 tab po QID. Following
intervention her oculogyric symptoms were reduced, and the patient was eventually
discharged.
Discussion
OGC is a rare dystonia recognized as sustained upward ocular deviations that are conjugate,
tonic and/or paroxysmal [3]. The condition often occurs after administration of typical
antipsychotics, antiepileptics, antiemetics, antimalarials or antidepressants. The patient may
exhibit bilateral dystonic elevation of visual gaze that may last for a prolonged period. An
accurate history is essential to choose between other causes of ocular deviation [8]. 
Although this condition is more frequent in children, it may be seen in elderly patients. It
occurs after an imbalance in the nigrostriatal dopamine/cholinergic tone. Dopamine D2
receptor blockade leads to an excess of striatal cholinergic output. This is usually dose
independent and may occur at therapeutic dosages [3]. Generally, men are more frequently
affected [9]. A family history of neurological disease and remote treatment with neuroleptics do
put patients at increased risk of OGC [10]. 
The pathophysiology of OGC remains elusive given our patient’s polypharmacy [11]. Her
longstanding disease of the nigrostriatal dopaminergic pathway with its functional disruption
of dopaminergic neurotransmission predisposed her to the development of OGC as has been
seen with postencephalitic parkinsonism cases [12].
Treatment of OGCs depends on the etiology of the condition [13]. In our case, the initial step
required the removal of the offending agent or the reduction of its dosage. In cases where this is
not possible, administration of anticholinergics, such as benztropine or antihistamines, is used
[14]. Repeated administration after 15 to 30 minutes may be needed [15].
Conclusions
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OGC is presently infrequently encountered in the general patient population. Second-
generation antidopaminergic medications are thought to have less adverse extrapyramidal side
effects as compared to first-generation medications. It was surprising for us to see OGC caused
by a medication with low risk for this adverse event. Ziprasidone-induced OGC is an atypical
phenomenon. It is unknown what role the novel antipsychotic pimavanserin has to play in the
resurgence of OGC with and without exposure to a second-generation antipsychotic.
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